KindlyMD (NASDAQ:NAKA) CEO David Bailey Acquires 4,918 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,918 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $5.12 per share, with a total value of $25,180.16. Following the transaction, the chief executive officer owned 3,180,394 shares of the company’s stock, valued at $16,283,617.28. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

KindlyMD Price Performance

Shares of NASDAQ:NAKA opened at $6.30 on Friday. The stock has a market capitalization of $112.77 million, a PE ratio of -0.18 and a beta of 15.95. The company’s 50-day moving average price is $4.48 and its two-hundred day moving average price is $7.24. KindlyMD, Inc. has a one year low of $3.33 and a one year high of $432.40.

KindlyMD (NASDAQ:NAKA) last released its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%.The company had revenue of $35.87 million for the quarter. On average, analysts anticipate that KindlyMD, Inc. will post -11.31 earnings per share for the current fiscal year.

KindlyMD News Roundup

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey bought 4,918 shares at an average price of $5.12, investing approximately $25,180. The purchase increased his direct ownership to 3.18 million shares and may signal confidence in the company’s long-term prospects. SEC insider ownership filing
• Neutral Sentiment: Maxim Group raised its EPS forecasts for several periods, including Q4 2026 to a loss of $0.48 per share from $0.60, Q1 2027 to a loss of $0.76 from $0.87, and Q2 2027 to a loss of $0.74 from $0.88. These revisions indicate expectations for somewhat smaller losses in those quarters, although KindlyMD remains unprofitable.
• Negative Sentiment: Maxim lowered its Q3 2026 EPS forecast to a loss of $0.49 from $0.43 and reduced its Q4 2027 estimate to a loss of $0.43 from $0.41. More significantly, its FY2027 forecast was cut to a loss of $2.12 per share from $1.44, pointing to weaker expected profitability over the full year.

Institutional Investors Weigh In On KindlyMD

A number of large investors have recently added to or reduced their stakes in the stock. J. Derek Lewis & Associates Inc. acquired a new stake in shares of KindlyMD during the 4th quarter worth $167,000. Virtu Financial LLC acquired a new stake in shares of KindlyMD during the 4th quarter worth approximately $151,000. Invesco Ltd. bought a new position in KindlyMD in the fourth quarter valued at approximately $211,000. NewEdge Advisors LLC bought a new stake in KindlyMD during the fourth quarter worth $316,000. Finally, Saba Capital Management L.P. acquired a new stake in shares of KindlyMD in the 4th quarter valued at $1,399,000.

Wall Street Analyst Weigh In

NAKA has been the subject of a number of recent analyst reports. TD Cowen increased their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. Finally, Wall Street Zen raised KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $22.33.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.